<DOC>
	<DOCNO>NCT01667107</DOCNO>
	<brief_summary>This single site study examine plasma alveolar compartment ( AC ) level posaconazole cystic fibrosis ( CF ) non-cystic fibrosis ( non-CF ) lung transplant recipient receive routine post-operative anti-fungal prophylaxis . Invasive fungal infection rate assess follow transplantation .</brief_summary>
	<brief_title>A Pharmacokinetic Analysis Posaconazole Lung Transplant Recipients ( MK-5592-105 )</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Scheduled undergo lung transplantation Able take oral/nasogastric medication Females childbearing potential , male , sexual partner male must use effective method birth control study 6 week complete study . Severe liver disease Current use cytochrome P450 ( CYP ) 3A4 inhibitor include terfenadine , astemizole , cisapride , pimozide , halofantrine quinidine within 7 day transplant Treatment posaconazole within 14 day transplant Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>